Pediatric topical steroid withdrawal syndrome: facts, misconceptions and communicating with patients and families.

Abstract

Purpose of review: Topical corticosteroids (TCS) have long been a mainstay in treating pediatric atopic dermatitis (AD). Topical steroid withdrawal syndrome (TSWS) has garnered increasing public attention, driven largely by social media discourse. This review aims to provide guidance for clinicians to effectively address concerns about pediatric TSWS in order to optimally manage AD in children.

Recent findings: An examination of the literature reveals several misconceptions surrounding TSWS. Research highlights the importance of standardized diagnostic criteria, caution with high- or inappropriate potency TCS, particularly in sensitive areas, and the need for provider-patient communication to improve therapeutic alliance.

Summary: TSWS is gaining recognition, and the lack of consensus on diagnostic standards and similarities with AD flares can result in misdiagnosis. This review highlights practical, evidence-based clinical approaches to discuss TSWS with patients/parents. Strategies to prevent adverse effects from TCS include appropriate potency selection and duration of treatment, utilizing gradual tapering protocols with proactive maintenance therapy, and addition of nonsteroidal anti-inflammatory therapies. Moreover, fostering an open, empathetic doctor-patient relationship can reduce unwarranted phobia around corticosteroids and ensure that TCS continue to be used optimally to treat AD and other inflammatory skin conditions. Thorough clinical guidance is essential to address patient/parent concerns about TSWS while working together toward an effective treatment plan for skin disease.